作者: #药闻简讯#$再生元制药(REGN)$抗 PD-1/IL-2RA/IL-2 融合蛋白REGN10597推进进入第 1 阶段 一项关于REGN10597(抗PD-1-IL2RA-IL2融合蛋白)在晚期实体器官恶性肿瘤患者中的安全性、耐受性、活性和药代动力学的1/2a期、开放标签、剂量递增和剂量扩大的首次人体研究,NCT06413680 全部讨论 贝福替尼有没有可...
Here, we describe the development of REGN10597, a PD-1-targeted, receptor-masked IL-2 immunocytokine with attenuated systemic IL-2 activity but maintained capacity to engage endogenous IL-2Ra on PD-1+ T cells. We will share preclinical data on in vitro characterization as well as in vivo ...